The PrecisionMed Traumatic Brain Injury Registry (TBI) is a biological sample bank of DNA, longitudinal CSF, RNA, serum and plasma linked to clinical data.

Driving the project is PrecisionMed Inc, which supplies human cerebral spinal fluid (CSF) and is a leader in clinical data procurement and sample management.

The registry is expected to help discovery and validate biomarkers for neurological disease.

It aims to enroll up to 2000 well-characterised participant donors who will be recruited, evaluated, clinically studied, and sampled from up to 10 investigative sites in the US.

Key aspects of donors’ clinical status will be evaluated every four months with simultaneous biological sampling.

These longitudinally collected, data-accompanied biospecimens will be available on request through PrecisionMed.

Custom requests for additional sample types, as well as more complex clinical, laboratory and/or radiographic evaluations within selected subpopulations will be entertained as the registry matures.

John Flax, CEO of PrecisionMed, said: “This project may yield important information for drug discovery, disease diagnosis, prediction of response to treatments and disease prognosis. The track record of PrecisionMed in this kind of collection is excellent and bodes well that the data and samples will be of the highest quality.

“Accurate phenotyping in TBI is critical for relating clinical changes to alterations in biomarkers and the development of disease-modifying treatments.”

PrecisionMed also has experience of CSF banking projects related to motor neurone disease, Alzheimer’s, mild cognitive impairment, schizophrenia, Parkinson’s, MS and “True Normal” populations.

It was founded in 1994 and has its human biobank in San Diego, California.